Risk assessment of potential CAR T candidates receiving a covalent BTK inhibitor for relapsed/refractory disease (Addendum to British Society for Haematology Guideline for the management of MCL, 2018)
Subscribe to be notified when new content is available
This website is intended for licensed healthcare professionals (HCPs) in Canada only.